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In this issue of Immunity, Xu et al. (2009) find that the transcription factor PLZF activates interferon-stimulated
genes and facilitates natural killer cell functions. Interferon-induced PLZF phosphorylation and histone de-
acetylase 1 recruitment probably mediates the repressor-to-activator conversion.PLZF (ZBTB16) belongs to a transcription
factor family that carries the Pox virus
and Zinc finger-Bric-a-brac Tramtrack
Broad complex (POZ-BTB) domain and
Kruppel type C2H2 zinc fingers in the
N- and C-terminal regions, respectively.
PLZF has been known as a transcriptional
repressor and regulates many target
genes through the promoter elements
recognized by the zinc fingers. Like other
family members, PLZF recruits nuclear
receptor corepressors 1 and 2 (NCoR1
and NCoR2) and histone deacetylases
(HDACs) to achieve repression. PLZF
controls development of skeletal elements
and spermatogenesis, and PLZF muta-
tions in humans are associated with
abnormalities related to these functions,
such as skeletal defects, genital hypo-
plasia, andmental retardation. PLZF is ex-
pressed in hematopoietic stemcells and in
peripheral lymphoid and myeloid cells,
with probable roles in regulating their
growth and differentiation. PLZF regulates
growth control genes such as MYC and
CDC6, partly by interactingwith the retino-
blastoma protein (McConnell et al., 2003).
It also mediates lymphocyte apoptosis
and is thought to take part in B cell chronic
lymphocytic leukemia.PLZF, inaddition, is
involved in acute promyelocytic leukemia,
where it is fused to retinoic acid receptor
a (RARa). In this issue of Immunity, Xu
et al. (2009) report that PLZF stimulates
transcription of a subset of interferon
(IFN)-stimulated genes (ISGs) and con-
tributes to IFN’s antiviral activity. More-
over, it commands natural killer cell
function.
Xu et al. (2009) microarray analysis indi-
cates that a relatively large fraction of
ISGs (perhaps more than 100) are regu-
lated by PLZF. These genes presumably
contain PLZF binding sites, in addition to
the IFN-stimulated response element intheir promoters, through which PLZF
and the ISGF3 complex (STAT1, STAT2,
IRF9) cooperatively activate transcription.
The cis-acting enhancement of transcrip-
tion has been described for a number of
ISGs that have binding sites for other tran-
scription factors, including proteins of the
NF-kB and Ets families. These cis-acting
proteins create diversity and complexity
to IFN responses (Hiscott et al., 2003).
Forexample,NF-kB, IRF,andAP1proteins
areassembledon the IFN-bpromoterupon
stimulation to formahypothetical structure
called the ‘‘enhanceosome,’’ leading to
efficient transcription. Some ISGs targeted
by PLZF, such as CXCL10, also carry an
NF-kB site, suggesting an additional layer
of diversity. Ets family proteins such as
PU.1, expressed highly in macrophages
and dendritic cells, also contribute to the
combinatorial diversity and cell-type-
dependent effects of IFNs. Xu et al. (2009)
show that PLZF-regulated ISGs include
those genes involved in antiviral defense,
such as RSAD2, OAS1, and TRIM22, and
accordingly PLZF-deficient mice are su-
sceptible to infection by Semliki Forest
virus and Encephalomyocarditis virus,
despite the fact that these mice produced
IFNs in normal amounts. Xu et al. (2009)
made a notable discovery that NK cells in
PLZF-deficient mice were not properly
activated upon IFN stimulation and were
deficient in tumor cell killing and granzyme
B production, highlighting the requirement
of PLZF in IFN-induced NK cell activation.
Combined with two recent studies sho-
wing that PLZF regulates development of
NKT cells, this work by Xu et al. (2009)
firmly establishes the role for PLZF in
shaping innate and adaptive immune
responses (Kovalovsky et al., 2008;
Savage et al., 2008).
NK cells express surface receptors that
recognize virus-infected cells as well asImmunitytumor cells (Caligiuri, 2008). NK cells are
activated in response to interferons and
other cytokines such as IL-12 and IL-15
to release the pore-forming proteins gran-
zyme B and perforin, which prompts
target cell apoptosis. Through the potent
cytotoxic activity, NK cells help to contain
viral infection, an important aspect of
innate immune responses. Accordingly,
deficiency in NK cells is associated with
susceptibility to herpes viruses and cyto-
megalovirus infection in human and
mice. It may be anticipated that PLZF
controls additional inducible activities of
NK cells beyond those found in this study.
Because NK cells are activated not only
by IFN but also by other cytokines, and
because PLZF activation seems to be
induced by signals not solely dependent
on IFNs (see below), PLZF may play
a broader role in NK cell activation not
limited to those linked to IFN signals.
This paper makes it amply clear that
when stimulated by IFN, PLZF acts as
abonafide transcriptional activator, rather
than a repressor as it was previously
defined. The authors’ mechanistic investi-
gation suggests that phosphorylationmay
be a key to the repressor-to-activator
switch: PLZF was phosphorylated within
the BTB domain, likely through the c-Jun
amino-terminal kinase (JNK) cascades,
rather than the JAK and TYK kinases of
the main IFN sinaling pathway. This phos-
phorylation was necessary for ISG induc-
tion. Previously, another domain of PLZF
was shown to be phosphorylated by cy-
clin-dependent kinase CDK2, which less-
ened transcriptional repression, suggest-
ing that phosphorylation can antagonize
repression (Costoya et al., 2008). Addi-
tionally, Xu et al. (2009) found that IFN
facilitates PLZF to bind to HDAC1, in
a manner dependent on the phosphoryla-
tion. The recruitment of a HDAC by PLZF30, June 19, 2009 ª2009 Elsevier Inc. 757
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ulated transcription, where ISG transcrip-
tion depends, for the most part, on HDAC
activity. A series of HDAC inhibitors are
known to block ISG induction and some
HDACs are found on the ISG promoters.
The requirement of HDAC activity in IFN-
stimulated transcriptionhasbeenpuzzling,
because IFN stimulation causes recruit-
ment of histone acetylases (HATs), in-
creasing chromatin acetylation in the ISG
genes. Does the PLZF-HDAC interaction
explain the IFN enigma? Not quite,
because ISGs not regulated by PLZF,
such as IFIT1, nevertheless depend on
Figure 1. Dynamic Interchange of PLZF
Function: A Model
IFN triggers PLZF phosphorylation, which converts
PLZF from a transcriptional repressor to an acti-
vator, a possible switch dependent on its
HDAC1-mediated deacetylation. The PLZF in this
state regulates antiviral innate immunity and
affects NK cell activity. Conversely, when unphos-
phorylated and acetylated by a nearby HAT, PLZF
acts as a classic repressor and regulates develop-
ment, cell growth, and apoptosis. The repressor
activity of PLZF has been described before.758 Immunity 30, June 19, 2009 ª2009 ElseHDAC activity. There appear to be other
mechanisms. A clue to the IFN enigma
may partly lie in the recently described
STAT1 acetylation (Kramer et al., 2009). It
was shown that STAT1, when phosphory-
lated after IFN stimulation, was then acety-
lated by the CREB binding protein (CBP),
one of many HATs. Acetylated STAT1
was then sequestered in the cytoplasm,
unable to stimulate transription. The role
of HDACs was to deacetylate STAT1, re-
storing the transcriptionally activate state.
Thus, the HDAC requirement for IFN-stim-
ulated transcription may not be at the level
of chromatin, butmay represent a dynamic
acetylation-deacetylationswitch that finely
tunes the function of an activator important
for ISG transcription. Dynamic, reciprocal
action of HATs and HDACs has been
proposed to explain the requirement of
HDACactivity for other genes.Further sup-
porting a dynamic acetylation-deacetyla-
tion exchange, some HDACs and HATs
are shown to be in very close physical
proximity (Yamagoe et al., 2003). The
STAT1 acetylation regulated by the HAT-
HDAC dynamics is intriguing, because
PLZF is also acetylated by p300, a HAT
closely related to CBP (Guidez et al.,
2005). Furthermore, it has been shown
that this acetylation is necessary for PLZF
to act as a transcriptional repressor. Is
there a parallel between STAT1 and PLZF
in this regard? Possibly: the transcriptional
status of PLZF might be dynamically
exchanged by acetylation and phosphory-
lation, given that PLZF is phosphorylated
upon IFN stimulation, analogous to
STAT1 (Figure 1).
The study by Xu et al. (2009) demon-
strates PLZF as a factor important for anti-
viral host defense and which commandsvier Inc.NKcell innate immunity. Thedual behavior
of PLZF as a transcriptional repressor and
activator and the dynamic posttransla-
tional modifications evoke many inter-
esting thoughts and will no doubt open
newavenuesof research in years to come.
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